Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)

This study has been completed.
Information provided by:
Millennium Pharmaceuticals, Inc. Identifier:
First received: July 9, 2003
Last updated: March 23, 2009
Last verified: March 2009
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2005
  Primary Completion Date: January 2005 (Final data collection date for primary outcome measure)